Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors01:20

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

388
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
388
Anticoagulant Drugs: Low-Molecular-Weight Heparins01:30

Anticoagulant Drugs: Low-Molecular-Weight Heparins

532
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
532
Formation of the Platelet Plug01:22

Formation of the Platelet Plug

2.7K
The platelet phase, the second stage of hemostasis, commences around 15-20 seconds after an injury. It follows and overlaps with the vascular phase, during which blood vessels constrict to minimize blood loss.
As the injured blood vessel contracts, endothelial cells undergo contraction, revealing collagen fibers in the basement membrane and underlying connective tissue. Furthermore, the plasma membrane of endothelial cells becomes adhesive, preparing the site for platelet adhesion. Platelets...
2.7K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Functional Organization of the Neonatal Basal Ganglia and Thalamus.

bioRxiv : the preprint server for biology·2026
Same author

Chronic Treatment with Renin-Angiotensin System Inhibitors at Hospital Admission is Associated with Improved Reperfusion and Mortality Among STEMI Patients Undergoing Mechanical Reperfusion: Insight from the ISACS-STEMI COVID-19 Registry.

Current vascular pharmacology·2026
Same author

BIBSNet: A deep learning baby image brain segmentation network for MRI scans.

Developmental cognitive neuroscience·2026
Same author

A four-step protocol to overcome loops/tortuosity during transradial coronary interventions: introducing the ''Serpentine'' technique.

Cardiovascular intervention and therapeutics·2026
Same author

Ultrasound-Guided Distal Radial Artery Recanalization (RETRY Study): Initial Case Series and Early Experience.

JACC. Case reports·2026
Same author

Examining Associations Between the Timing of Maternal Depressive Symptoms, Parenting Behaviors, and Child Outcomes.

Journal of the American Academy of Child and Adolescent Psychiatry·2025

Related Experiment Video

Updated: May 8, 2025

Microfluidics in Assessing Platelet Function
06:47

Microfluidics in Assessing Platelet Function

Published on: November 8, 2024

706

Platelet Function Testing and Genotyping for Tailoring Treatment in Complex PCI Patients.

Athanasios Moulias1, Angeliki Papageorgiou1, Dimitrios Alexopoulos2

  • 1Department of Cardiology, General University Hospital of Patras Patras, Greece.

US Cardiology
|December 25, 2024
PubMed
Summary

Optimizing dual antiplatelet therapy (DAPT) for complex percutaneous coronary intervention (PCI) patients is challenging. This review explores platelet function testing and genotyping for tailoring antiplatelet treatment, noting limited current evidence.

Keywords:
P2Y12 receptor inhibitorsPercutaneous coronary interventioncomplex percutaneous coronary interventiondual antiplatelet therapygenotypingplatelet function testing

More Related Videos

Dynamic Multiparameter Platelet Function Assessment Using a Capacitive Biosensor
06:32

Dynamic Multiparameter Platelet Function Assessment Using a Capacitive Biosensor

Published on: May 2, 2025

135
A Microfluidic Flow Chamber Model for Platelet Transfusion and Hemostasis Measures Platelet Deposition and Fibrin Formation in Real-time
09:38

A Microfluidic Flow Chamber Model for Platelet Transfusion and Hemostasis Measures Platelet Deposition and Fibrin Formation in Real-time

Published on: February 14, 2017

13.7K

Related Experiment Videos

Last Updated: May 8, 2025

Microfluidics in Assessing Platelet Function
06:47

Microfluidics in Assessing Platelet Function

Published on: November 8, 2024

706
Dynamic Multiparameter Platelet Function Assessment Using a Capacitive Biosensor
06:32

Dynamic Multiparameter Platelet Function Assessment Using a Capacitive Biosensor

Published on: May 2, 2025

135
A Microfluidic Flow Chamber Model for Platelet Transfusion and Hemostasis Measures Platelet Deposition and Fibrin Formation in Real-time
09:38

A Microfluidic Flow Chamber Model for Platelet Transfusion and Hemostasis Measures Platelet Deposition and Fibrin Formation in Real-time

Published on: February 14, 2017

13.7K

Area of Science:

  • Cardiology
  • Pharmacology

Background:

  • Dual antiplatelet therapy (DAPT) with aspirin and a P2Y12 inhibitor is standard post-percutaneous coronary intervention (PCI).
  • Complex PCI (C-PCI) patients face higher ischemic risks, complicating DAPT strategy selection.
  • Balancing ischemic and bleeding risks in C-PCI necessitates individualized DAPT approaches.

Purpose of the Study:

  • To critically evaluate the utility of platelet function testing and genotyping for tailoring DAPT in C-PCI patients.
  • To review current evidence on personalized antiplatelet therapy in this specific subpopulation.

Main Methods:

  • Literature review of clinical trials and studies.
  • Analysis of evidence regarding platelet function testing and genotyping in C-PCI patients.
  • Assessment of treatment individualization strategies for DAPT.

Main Results:

  • Existing trials on platelet function testing and genotyping in PCI populations show conflicting and largely neutral results.
  • The role of these tools for optimizing DAPT in C-PCI remains uncertain due to limited dedicated research.
  • Individualization of DAPT potency and duration is an evolving strategy for C-PCI.

Conclusions:

  • Current evidence is insufficient to definitively recommend platelet function testing or genotyping for guiding DAPT in C-PCI patients.
  • Further dedicated studies are required to establish the clinical utility of these personalized approaches.
  • Optimizing antiplatelet therapy in C-PCI remains an area needing further investigation.